Business · 07/04/2014Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for MELAFIND SYSTEM Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for MELAFIND SYSTEM, a medical device, in accordance with patent extension laws, following a submission to the Director of Patents and Trademarks at the US Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →